Malaria Clinical Trial
Official title:
Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)
Microscopy remains a key indicator in drug efficacy testing performed in the context of
clinical trials for monitoring existing antimalarials or in the context of regulatory
clinical trials for registration of new drugs. It is one of the main diagnostic methods for
malaria diagnosis in general, as in an ideal setting it can provide low-cost accurate
diagnosis, determine the density of parasites in the blood, and accurately differentiate
between different malaria parasite species, characteristics vital to the implementation of
global plans for drug efficacy monitoring. Malaria rapid tests (RDTs), while useful for case
management, do not provide information on the parasite density nor the species
differentiation necessary for research and drug efficacy assessment. Microscopy therefore
retains key advantages over a number of newer technologies, but its reliability is severely
impeded by dependence on high technical competence of the human operators as well as
availability of high quality equipment and reagents. Recent studies have demonstrated the
frequent poor specificity and sensitivity associated with manual microscopy diagnostics in
operational conditions , , . Advances in digital microscopy performance and affordability
have now opened the door to potentially significant improvements in the performance of
malaria diagnostic microscopy, overcoming serious deficiencies in current drug efficacy
assessment, and more broadly in malaria diagnosis and management.
Intellectual Ventures Laboratory (IVL), in collaboration with Global Good Fund (GG), has
developed an initial microscope prototype to support its research into dark field imaging of
unstained malaria slides. The system consists of low cost electromechanical components for
scanning a standard slide, an optical train with a high numerical aperture objective, and an
image capture system. Captured images are analyzed with custom image analysis software
developed at GG/IVL, using algorithms that are designed for automatic malaria diagnosis,
without user input. Additionally, image processing algorithms have been built around
detection of Giemsa-stained malaria slides which is the current standard for malaria
microscopy. Initial results show excellent potential for sensitivity and specificity which
exceeds that of typical manual microscopists in the field. Based on the positive market and
needs assessment in January, 2013, given by stakeholders in the malaria diagnostics
community, GG/IVL are pursuing improvement and integration of this algorithm into a portable
microscope platform with characteristics similar to the prototype microscope already
developed at GG/IVL for dark field imaging. The prototype Autoscope was first tested in field
settings in Thailand in Nov 2014 - Jan 2015 at clinics operated by the Shoklo Malaria
Research Unit (SMRU). The goal of the first field evaluation was to assess the Autoscope in
with respect to its diagnostic performance and also its suitability for harsh conditions
typically encountered in field clinics. Further, user feedback on the design and
functionality was sought. The Autoscope and the accompanying image analysis algorithms have
since been further developed and a new version is now available for testing.
Study Design & Procedure The primary purpose of this evaluation is to quantify the diagnostic
performance of the Autoscope version 2 prototype in a field setting. The performance of the
Autoscope version 2 prototype will be assessed by scanning of negative and positive slides
with the Autoscope version 2 and comparing the results with expert microscopy. Plasmodium
genus- and species-specific PCR will also be performed as an additional confirmatory test for
the detection of malaria parasites and their species if present. Testing by microscopy and
Autoscope will be performed in field clinic settings on Giemsa-stained stained slides
prepared from febrile patient blood collected from a finger-prick. Patient recruitment will
aim to recruit up to 80 slide-confirmed malaria cases (P. falciparum, P. vivax or other
species) per country (i.e., total 160 cases) have been included in the study.
Patient procedures Patients who present at the clinic will be screened to assess eligibility.
A consent form in the local languages (Karen or Burmese at SMRU sites, Bahasa in South
Sumatera at EOCRU site) will be administered to patients with a description of the intentions
of this study in order to protect human subjects before any study specific procedures are
conducted. It will be clearly stated that participation is voluntary and that the subject or
guardian is free to discontinue participation or withdraw consent to participate at any time
for any reason without prejudice to future care, and with no obligation to give the reason
for discontinuation nor for withdrawal. The subject or guardian will be allowed as much time
as needed to consider the information and the opportunity to question the authorized research
member, or other independent parties to decide whether they will (or allow his/her charge to)
participate in the study. Written informed consent will then be obtained by means of subject
or guardian dated signature or thumb print (if unable to write), with signed and dated
signature of a witness and dated signature of the person who presented and obtained the
informed consent. All individual written informed consent forms will be stored securely.
Children capable of understanding the study (approximately 7 years of age or above for SMRU
sites and 12 years of age or above for EOCRU sites) will be asked to sign an assent form. A
copy of the signed informed consent document(s) will be given to the participants.
Once informed consent has been obtained, the subject number will be assigned and recorded on
the screening and enrollment log. A few drops of blood (maximum of 150-200 µL) will be
obtained from a finger-prick and study-specific laboratory procedures as described below will
be performed. The patient will then receive clinical care as appropriate according to the
routine procedures.
Laboratory procedures All laboratory procedures will be performed according to the applicable
standard operating procedures.
At the clinics (Wang Pha, Mawker Tai, Thailand and Hanura, South Sumatera, Indonesia)
- Blood collection from finger-prick (maximum 150-200 µL), which will be used to prepare
slides.
- Perform malaria RDT (part of routine practice for malaria detection), prepare 2 slides
each with thick and thin blood films, store remainder of blood sample for PCR to detect
and determine species of malaria parasites
- Microscopy of Giemsa-stained blood films (microscopists will remain blinded to RDT and
Autoscope results), record results
- Run Autoscope detection, record results, store images captured by the device At SMRU and
EOCRU
- Review of all slides by expert microscopists (microscopists will remain blinded to RDT
and Autoscope results)
- PCR to detect and determine species of malaria parasites At the WWARN Laboratory,
Bangkok
- Review of field data to identify discrepant readings and tie-breaker readings in case of
discordance between results obtained on site and on re-checking of the slides Quality
Assurance
- Quality control performed by WWARN expert microscopists on 20% randomly selected slides
or 25 positive and 25 negative slides per country, whichever is greater
The funder is Intellectual Ventures Lab/ Global Good and grant reference PA No.3.
Summary of Results
The sensitivity and specificity of the Autoscope version 2 prototype were 92.2% and 89.2%,
respectively. The accuracy was 90.03%. Parasite species were correctly determined in 132/158
slides (83.5%) and kappa value for species detection was 0.60(0.45-0.73). 45.6% of the
parasite density estimates from the Autoscope were within 25% range of the reference results,
yielding the interclass correlation coefficient (ICC) of 0.78 (95%CI: 0.70-0.83).
Bland-Altman plot showed no systematic bias of the measurement. Differences between the 2
counts increased in higher parasite density (correlation coefficient (r) = 0.861, P < 0.001).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |